Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine

Thoracic Paravertebral Blocks Clinical Trial

Official title:

Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03677115
• Other study ID #: 201707158
• Status: Withdrawn
• Phase: Phase 4
• Start date: November 1, 2018
• Est. completion date: March 30, 2023

Study information

• Verified date: November 2021
• Source: China Medical University, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration.

Description:

The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration. The effects of dexmedetomidine have only been compared at lower doses. This trial examined the effect of greater dose of dexmedetomidine on thoracic paravertebral block analgesia duration.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 30, 2023
• Est. primary completion date: March 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients were included in the study if they were ethnic Chinese,

• American Society of Anesthesiologists (ASA) physical status I or II,

• candidates for general anesthesia undergoing thoracic surgery

Exclusion Criteria:

• Patients were excluded if they do not want to cooperate with the test,

• had a history of radial artery puncture or coronary artery bypass grafting,

• had acute vessel trauma,or had been diagnosed with Raynaud' disease,

• had suffered from mental or neurological disorders

Related Conditions & MeSH terms

• Aneurysm, Dissecting
• Thoracic Paravertebral Blocks

Intervention

Drug:
• Dexmedetomidine
combination of ropivacaine and dexmedetomidine 20 ug every time

Locations

Country	Name	City	State
China	the First Hospital of China Medical University	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
China Medical University, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of analgesia duration	Change of thoracic paravertebral block analgesia duration	Change from Baseline to 3 days after surgery